1. Going Beyond EXTREME in Head and Neck Cancer

3. This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Introduction

5. KEYNOTE-012 Long-Term Follow-Up

6. CheckMate-141 Phase 3 Trial

7. CheckMate-141 Results

8. KEYNOTE-040 Phase 3 Trial

9. Notes on KEYNOTE-040

10. Further Notes on Checkpoint Inhibition in the Second Line

11. PD-L1 as a Biomarker

12. Use of Biomarkers

13. KEYNOTE-048 First-Line Trial Trial Design

14. Use of CPS in KEYNOTE-048

15. KEYNOTE-048 OS Results of Pembrolizumab Monotherapy vs EXTREME

16. KEYNOTE-048 Results of Pembrolizumab Monotherapy vs EXTREME (cont)

17. KEYNOTE-048 OS Results of Pembrolizumab + Chemotherapy vs EXTREME, Total Population

18. KEYNOTE-048 Results of Pembrolizumab + Chemotherapy vs EXTREME, Total Population (cont)

19. Notes on KEYNOTE-048

20. Comparison With Chemoimmunotherapy in NSCLC

21. Further Notes on KEYNOTE-048

22. Study Implications

23. Ongoing Phase 3, First-Line Trials

24. Thoughts About the Future of Immunotherapy in SCCHN

25. Abbreviations

26. Abbreviations (cont)